Sanofi-aventis U.S. has filed a nearly $3 million lawsuit in Manhattan Supreme Court alleging Tolmar Pharmaceuticals breached agreements linked to fees owed to Sanofi for marketing Tolmar’s prostrate cancer drug Eligard.
The lawsuit brought by Sanofi-aventis U.S., an arm of the French global pharmaceutical company, contends Tolmar has refused for the last two years to pay more than $2,907,467 in fees associated with Sanofi’s contract to market the Tolmar-developed drug in the United States.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
